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Abstract
Background: Work disability remains a significant problem in ankylosing spondylitis (AS) and rheumatoid arthritis
(RA), despite biological therapy. This study aimed to test the hypothesis that the prevalent symptom of fatigue
longitudinally predicts work disability among RA and AS patients commencing etanercept.
Methods: Two observational studies, comprising RA and AS etanercept commencers, respectively, were analysed.
Both provided data on work disability over 1 year and a comprehensive set of putative predictors, including fatigue.
A series of repeated measures models were conducted, including baseline variables, visit (6/12 months), and the
interaction between visit and each of the explanatory variables.
Results: A total of 1003 AS and 1747 RA patients were assessed. For AS, fatigue was significantly associated with
presenteeism (linear mixed model coefficient 3.75, 95% confidence interval (CI) 2.14 to 5.36) and activity impairment
(2.62, 1.26 to 3.98), but not with work productivity loss (1.81, −0.40 to 4.02) or absenteeism (generalised linear mixed
model odds ratio (OR) 1.18, 95% CI 0.92 to 1.51). In RA, fatigue was associated with presenteeism (coefficient 3.44,
95% CI 2.17 to 4.70), activity impairment (1.52, 0.79 to 2.26), work productivity loss (4.16, 2.47 to 5.85), and
absenteeism (OR 1.23, 95% CI 1.02 to 1.49). The lack of significant interactions between fatigue and visit supported
a consistent effect of baseline fatigue over time.
Conclusions: Among patients beginning etanercept therapy, fatigue has a significant and independent effect on
absenteeism, presenteeism, productivity loss, and activity impairment for RA patients and a significant but
dimension-selective effect on work disability among AS patients.
Trial registration: ClinicalTrials.gov, NCT00544557. Registered on 16 October 2007. ClinicalTrials.gov, NCT00488475.
Registered on 20 June 2006.
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Background
Inflammatory rheumatic diseases, such as rheumatoid
arthritis (RA) and ankylosing spondylitis (AS), are a sub-
stantial cause of work disability [1], a key outcome for
both the patient and society. Estimates indicate that
within 10 years of symptom onset up to 70% of patients
become work disabled [2], rising to approximately 90%
as disease duration increases [3].
Biological therapies have significantly minimised the
physical sequelae of poorly controlled inflammation,
such as joint destruction [4–6]. This in turn has been
associated with an improvement in patient outcomes in-
cluding those relating to work capacities [4–8]. Despite
these gains, work disability remains an issue for the
majority of RA and AS patients and it has become in-
creasingly clear that the determinants of work disability
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in inflammatory diseases are not necessarily inflamma-
tory in origin [9–11].
Fatigue, a patient priority inconsistently associated
with inflammation [12], is possibly one such determin-
ant. This symptom represents a persistent, unmanage-
able, and unpredictable issue [13–15] which is reported
by up to 80% of patients with AS and RA. The impact of
fatigue is multi-dimensional. For example, levels of phys-
ical activity are reduced and relationships are harmed
[13, 14]. Yet the symptom is poorly managed, and many
patients feel this subject is ignored by their clinicians.
Subsequent attempts to self-manage by trial and error
are typically unsuccessful [14, 16].
Anecdotally, patients have identified fatigue as a prin-
cipal barrier to employment and productivity [13, 16].
The subsequent need to reduce work hours, relinquish
roles, or even retire from work altogether have been
attributed to the emotional, physical, and cognitive
consequences of the symptom [3, 13, 16, 17]. How-
ever, the empirical evidence supporting these attribu-
tions is limited.
To date, analyses of the relationship between fatigue
and work disability have generally examined cross-
sectional data in small sample sizes [3, 18] and know-
ledge regarding the long-term nature of the relationship
is sparse. Indeed, a previous systematic review of work
disability predictors in RA surprisingly failed to identify
any studies that have evaluated fatigue as a putative fac-
tor [19]. Furthermore, no study designs examining the
impact of fatigue have employed a comprehensive meas-
ure of work disability which is necessary to adequately
capture this complex multi-dimensional construct. To
evaluate the different components, which include pres-
enteeism (reduced performance at work due to ill
health) and productivity in addition to the traditionally
applied measure of absenteeism, suitably designed and
detailed tools should be applied [20]. Finally, to our
knowledge, no investigation has compared the fatigue-
work disability relationship between distinct rheumatic
disorders.
We have previously observed that patients commonly
report continuing high levels of fatigue despite success-
fully attaining clinical remission (Disease Activity Score
(DAS28) < 2.6) 6 months after commencing biologic
therapy [21]. We now hypothesise that, in this current
era of biological therapies, fatigue is independently asso-
ciated with continuing levels of work disability among
patients with inflammatory rheumatic diseases. Specific-
ally, this study aimed to examine whether fatigue inde-
pendently predicts different work disability dimensions,
adjusting for clinical and psychosocial factors, over 1
year in working patient populations commencing etaner-
cept, a commonly prescribed biologic. Furthermore, we
obtained data from two near-identical studies on AS and
RA to compare the relative impact of fatigue on work
disability between these two common, but pathologically
distinct, inflammatory rheumatic diseases.
Methods
Data were obtained from 6518 patients recruited to
one of two observational studies on patients with
clinician-confirmed AS (n = 1663; clinical study num-
ber NCT00544557) or RA (n = 4855; clinical study
number NCT00488475) who were commencing eta-
nercept as part of routine clinical practice in Germany.
Ethical approval for the original studies was obtained from
the Ethics Committee of the State Chamber of Physicians
(Landesaertzekammer; NCT00544557, 21 September
2007; NCT00488475, 15 September 2006).
Both cohorts were followed-up for 1 year. Data col-
lected at baseline, 6 months, and 1 year contributed to
this study. Of the variables captured, data obtained for
these analyses comprised fatigue, work disability, demo-
graphics, clinical, and psychosocial status.
Fatigue
Fatigue was measured using visual analogue scales
(VAS) anchored from ‘no fatigue’ to ‘worst possible fa-
tigue’. Although limited to providing a global assessment
of fatigue, VAS have been extensively used and validated
across most of the rheumatic disease spectrum. In the
AS cohort, the VAS was extracted from the self-reported
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) questionnaire and was thus scored 0–10 cm. In
the RA cohort, the VAS was originally scored 0–100 mm
but was converted into a 0–10 cm scale to facilitate
comparability.
Work disability
Work disability was measured using the six-item self-
report Work Productivity and Activity Impairment—
Special Health Problems (WPAI:SHP). The WPAI:SHP
assesses the impact of the participant’s condition on
work and daily activities for the past 7 days. The WPAI:
SHP has been validated for use in both AS [22] and RA
[23], and can be modified for any health problem by spe-
cifying the disease/condition of interest in the questions.
The questionnaire comprises four subscales: absenteeism,
presenteeism, overall work impairment (absenteeism plus
presenteeism), and daily activity impairment. Scores are
transformed into impairment percentages ranging from 0
to 100%, with high scores indicating greater impairment
and reduced productivity.
The absenteeism subscale was heavily skewed, with
over 80% of patients reporting no absenteeism. This
variable was therefore dichotomised (as 0 or > 0) for the
analysis; all other subscales were treated as continuous
variables.
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Demographics
Of the information captured at baseline, participant age,
sex, and current working status (currently employed or
not) were of interest.
Clinical status
Physicians assessed disease activity using an 11-point
Likert scale, from 0 ‘no disease activity’ to 10 ‘high
disease activity’ in the AS cohort, and a 0–100 mm VAS
from 0 mm ‘no disease activity’ to 100 mm ‘maximum
possible disease activity’ in the RA cohort. C-reactive
protein (CRP) was measured from blood samples taken
at baseline.
Psychosocial status
Self-reported pain and anxiety/depression were considered
potential confounders. Pain was recorded by an 11-point
Likert scale, from 0 ‘least possible pain’ to 10 ‘worst pos-
sible pain’ in the AS cohort, and by a 0–100 mm VAS
from 0 mm ‘minimum possible pain’ to 100 mm ‘max-
imum possible pain’ in the RA cohort. Anxiety/depression
was recorded using the anxiety and depression field of the
European Quality of Life 5 Dimensions (EQ-5D) question-
naire. The EQ-5D has been validated for use in RA and
AS populations [24, 25] and has three possible ordinal
outcomes: no problems, some problems, and extreme
problems.
Analysis
In those participants who were employed at baseline
(irrespective of proportion of work impairment due to
absenteeism), repeated measures models (repeated by
visit within subject) using a compound symmetry co-
variance structure were used to investigate the longitu-
dinal relationship between each work disability score at
6 and/or 12 months and baseline fatigue. For absentee-
ism (dichotomised as 0 or > 0), a generalised linear
mixed model was used with binomial distribution and
logit link, while a linear mixed model was used for the
remaining subscales.
Initial models included baseline fatigue and other po-
tential baseline predictors as explanatory variables, visit
(6/12 months), and the interaction between visit and
each of the explanatory variables. The model was then
manually stepwise reduced, removing the most non-
significant interactions at each step and then the most
non-significant main effects (unless there was a signifi-
cant interaction with visit, in which case the main effect
was retained to allow the total effect at each visit to be
quantified). A nominal 5% level of significance was used,
but terms were retained at the 10% level if they modified
the fatigue effect.
All continuous variables included in the models
were standardised to aid non-statistical comparison
between the diseases. Such that the resultant regres-
sion coefficients should be interpreted as the number
of standard deviations the dependent variable would
change per one standard deviation increase in the
predictor.
All analyses were carried out using SAS© version 9.3.
Results
Of 1663 AS patients, 1003 (60%) were working at base-
line and could be included in this analysis. The majority
(63%, n = 635) were male, with a mean age of 40.7 years
(standard deviation 10.6). Of 4855 RA patients, 1747
(36%) were working at baseline and were eligible for this
analysis. Just under three-quarters (72%) were female,
with a mean age of 47.3 years (9.9) (Table 1).
Apart from the expected greater proportion of
male AS versus RA patients, the cohorts were com-
parable at baseline. No relevant differences in clin-
ical, psychosocial, or work disability domains were
observed.
Fatigue as a predictor of work and activity impairment in
AS
Of the variables entered into the model, only baseline
absenteeism (odds ratio (OR) 4.59, 95% confidence inter-
val (CI) 2.91 to 7.25) and having some, versus no, prob-
lems with anxiety or depression (OR 1.77, 95% CI 1.12
to 2.80) were associated with a statistically significant in-
crease in the odds of absenteeism at 6 and 12 months
(Table 2). Although fatigue at baseline was associated
with a small increase in the odds of absenteeism, the re-
sult was not significant (OR 1.18, 95% CI 0.92 to 1.51).
Fatigue at baseline was a statistically significant pre-
dictor of presenteeism at 6 and 12 months (standardized
beta co-efficient (β) 3.75, 95% CI 2.14 to 5.36) unit in-
crease in impairment. Age (β 4.48, 95% CI 3.07 to 5.89)
and presenteeism at baseline (β:6.25, 95% CI 4.67 to 7.82)
were also associated with a statistically significant increase
in presenteeism. Being male was associated with reduced
impairment of presenteeism over time (β −4.65, 95% CI
−7.62 to −1.68) as was baseline CRP level (β −1.83, 95%
CI −3.53 to −0.13).
Increased work productivity loss over time was pre-
dicted by age (β 5.22, 95% CI 3.52 to 6.93) and work
productivity loss at baseline (β 6.62, 95% CI 4.53 to 8.71),
as well as having some (β 3.76, 95% CI 0.09 to 7.42) or
extreme (β 12.32, 95% CI 1.38 to 23.26) problems with
anxiety or depression, compared with no problems.
Fatigue at baseline was not associated with work prod-
uctivity loss (β 1.81, 95% CI −0.40 to 4.02) and, al-
though pain was at 6 months (β 2.77, 95% CI 0.34 to
5.20), the significant interaction between visit and pain
score at baseline suggests a negligible effect of base-
line pain by 12 months.
Druce et al. Arthritis Research & Therapy  (2018) 20:96 Page 3 of 9
Finally, increased activity impairment during the course
of the study was associated with age (β 5.07, 95% CI 3.96
to 6.19), having some (β 3.27, 95% CI 0.85 to 5.68) or
extreme (β 10.74, 95% CI 5.35 to 16.14) problems with
anxiety or depression compared with no problems, having
increased fatigue at baseline (β 2.62, 95% CI 1.26 to 3.98),
and higher impairment at baseline (β 8.51, 95% CI 7.14 to
9.87). Higher baseline inflammation, as measured by CRP,
was associated with a reduction in activity impairment at
6 and 12 months (β −2.76, 95% CI −3.85 to −1.67).
Fatigue as a predictor of work and activity impairment in
RA
In patients with RA, the likelihood of absenteeism at 6
and 12 months was significantly higher in those with
more fatigue at baseline (OR 1.23, 95% CI 1.02 to 1.49),
who were older (OR 1.20, 1.00 to 1.44), and who re-
ported absenteeism at baseline (OR 4.75, 3.35 to 6.75).
Greater inflammation at baseline was associated with a
decreased likelihood of reporting absenteeism over the
course of the study (OR 0.82, 95% CI 0.68 to 0.98)
(Table 3).
Increased presenteeism over time was significantly pre-
dicted by baseline fatigue (β 3.44, 95% CI 2.17 to 4.71) and
age (β 1.44, 95% CI 0.26 to 2.63). Presenteeism at baseline
was associated with a statistically significant increase in
presenteeism at 6 and 12 months (Table 3).
Of all the putative predictors entered into the models,
only fatigue (β 4.16, 95% CI 2.47 to 5.85) and baseline
work productivity loss (β 9.43, 95% CI 7.74 to 11.12) were
associated with increased work productivity loss over
time. Increased activity impairment at 6 and 12 months
was significantly associated with fatigue (β 1.52, 95% CI
0.79 to 2.26), older age (β 3.25, 95% CI 2.61 to 3.90),
and having some (β 2.80, 95% CI 1.40 to 4.20) or ex-
treme (β 5.81, 95% CI 2.82 to 8.79) problems with anxiety
or depression, compared with no problems. Baseline
activity impairment was associated with greater impair-
ment over time (β 9.41, 95% CI 8.59 to 10.23 at
6 months), but the significant interaction between base-
line activity impairment and visit suggested a reduced
effect was present by 12 months.
Comparison of fatigue as a predictor of work disability
between RA and AS
The most consistent predictive factor for both populations
was the baseline level of the predicted work outcome.
Otherwise, although overall fatigue was a commonly
Table 1 Baseline characteristics of the 1003 AS patients and 1747 RA patients who were working at baseline
Parameter AS n RA n
Age (years), mean (SD) 40.7 (10.6) 1003 47.3 (9.9) 1747
Female, % 36.7 1003 72.4 1747
Disease duration (years), mean (SD) 7.3 (7.8) 979 7.9 (7.6) 1654
Disease activity 0–10 Likert, mean (SD) 6.3 (1.7) 1000 –
0–100 mm VAS, mean (SD) – 59.1 (18.0) 1724
CRP (mg/dL), median (min, max) 1.0 (0.0, 42.7) 906 0.9 (0.0, 20.0) 1534
Fatigue 0–10 cm VAS, mean (SD) 5.6 (2.4) 997 –
0–100 mm VAS, mean (SD) – 57.4 (24.9) 1735
Pain 0–10 Likert, mean (SD) 6.3 (2.2) 990 –
0–100 mm VAS, mean (SD) – 61.6 (21.4) 1736
Anxiety/depression
(EQ-5D)
No problems, % 53.6 998 52.1 1738
Some problems, % 42.7 44.4
Extreme problems, % 3.7 3.6
WPAI:SHP
% work time missed due to AS/RAa No timed missed 61.9 776 61.3 1293
Some time missed 38.1 38.7
% impairment while working due to AS/RAb, mean (SD) 48.3 (26.9) 889 49.5 (27.1) 1530
% overall work impairment due to AS/RAc, mean (SD) 52.9 (29.8) 716 54.1 (29.0) 1171
% activity impairment due to AS/RAd, mean (SD) 53.4 (24.6) 990 54.0 (24.9) 1718
aAbsenteeism
bPresenteeism
cWork productivity loss
dActivity impairment
AS, ankylosing spondylitis; CRP, C-reactive protein; EQ-5D, European Quality of Life 5 Dimensions; RA, rheumatoid arthritis; SD, standard deviation; VAS, visual
analogue scale; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems
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identified independently significant predictor of work dis-
ability in both RA and AS patients, its effect appears more
prominent among RA patients in relation to other puta-
tive predictors while, in AS patients, the effect of anxiety/
depression was relatively stronger. In contrast, other vari-
ables such as disease activity and pain did not appear to
be important in these study samples.
When considering the associations between fatigue
and the different work disability components, both
similarities and differences existed across RA and AS
patients. For both diseases, fatigue was associated with
presenteeism (AS: β 3.75, 95% CI 2.14 to 5.36; RA: β 3.
44, 95% CI 2.17 to 4.71) and activity impairment (AS:
β 2.62, 95% CI 1.26 to 3.98; RA: β 1.52, 95% CI 0.79 to
2.26). However, fatigue was identified as a significant
predictor of all four work disability components under
investigation in our RA population, while fatigue was
not identified as an independent predictor of absen-
teeism or work productivity loss among AS patients.
In both studies, no interactions between fatigue and
Table 2 Baseline variables predictive of WPAI:SHP subscales at 6 and 12 months in 1003 AS patients
Predictor Odds ratio (95% CI)
Outcome: absenteeism
Fatigue 1.18 (0.92 to 1.51)
% work time missed due to AS (> 0 vs 0) 4.59 (2.91 to 7.25)
Anxiety/depression Some vs none 1.77 (1.12 to 2.80)
Extreme vs none 0.87 (0.26 to 2.86)
Extreme vs some 0.49 (0.15 to 1.57)
Visit 12 months vs 6 months 1.001 (0.70 to 1.44)
Predictor Standardized beta-coefficient
(β) (95% CI)
Outcome: presenteeism
Fatigue 3.75 (2.14 to 5.36)
Male vs female −4.65 (−7.62 to −1.68)
Age (years) 4.48 (3.07 to 5.89)
CRP −1.83 (−3.53 to −0.13)
% impairment while working due to AS 6.25 (4.67 to 7.82)
Visit 12 months vs 6 months −0.99 (−2.57 to 0.60)
Outcome: Work productivity loss
Fatigue 1.81 (−0.40 to 4.02)
Male vs female −3.57 (−7.29 to 0.15)
Age (years) 5.22 (3.52 to 6.93)
Pain 2.77 (0.34 to 5.20)
Pain at 12 months vs pain at 6 months −2.49 (−4.49 to −0.49)
% overall work impairment due to AS 6.62 (4.53 to 8.71)
Anxiety/depression Some vs none 3.76 (0.09 to 7.42)
Extreme vs none 12.32 (1.38 to 23.26)
Visit 12 months vs 6 months −1.42 (−3.42 to 0.59)
Outcome: Activity impairment
Fatigue 2.62 (1.26 to 3.98)
Age (years) 5.07 (3.96 to 6.19)
CRP −2.76 (−3.85 to −1.67)
% activity impairment due to AS 8.51 (7.14 to 9.87)
Anxiety/depression Some vs none 3.27 (0.85 to 5.68)
Extreme vs none 10.74 (5.35 to 16.14)
Visit 12 months vs 6 months −1.10 (−2.35 to 0.15)
AS, ankylosing spondylitis; CI, confidence interval; CRP, C-reactive protein; RA, rheumatoid arthritis; VAS, visual analogue scale; WPAI:SHP, Work Productivity and
Activity Impairment—Special Health Problems
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visit were significant, suggesting a consistent effect of
fatigue over the following 12-month period.
Discussion
In this large study, fatigue had a significant and inde-
pendent effect on all work disability dimensions at 6 and
12 months for patients with RA commencing etanercept.
For AS patients who commenced etanercept, fatigue was
identified as having a significant effect on presenteeism
and overall activity impairment only. Across both studies,
the lack of significant interactions between fatigue and
visit suggests a consistent effect of baseline fatigue over
the following 12-month period.
This study adds to the growing body of evidence
highlighting the great importance of this previously ig-
nored symptom among patients with inflammatory
rheumatic diseases, and particularly emphasizes the eco-
nomic impact of fatigue for both the individual and
society as a whole. The existence of this relationship in
the context of expensive biological treatment serves to
enhance the economic issues further—despite their pre-
scription, work disability remains an issue. The data pre-
sented herein support the case for targeting fatigue in
parallel (employing, for example, non-pharmacological
approaches) with a view to optimizing work-related out-
comes and so providing even greater societal returns to
the considerable pharmacological investments that glo-
bal health systems have made in recent years. Further-
more, the study uniquely indicates that fatigue is
importantly associated with work disability across two
disparate disease populations, although the apparent dif-
ferential effect on work disability dimensions should en-
courage some consideration of disease-specific issues
during the development of appropriate interventions.
The few previous studies to quantitatively examine the
relationship between RA and AS fatigue and work
Table 3 Baseline variables predictive of WPAI:SHP subscales at 6 and 12 months in 1747 RA patients
Predictor Odds ratio (95% CI)
Outcome: absenteeism
Fatigue 1.23 (1.02 to 1.49)
Age (years) 1.20 (1.00 to 1.44)
CRP 0.82 (0.68 to 0.98)
% work time missed due to RA (> 0 vs 0) 4.75 (3.35 to 6.75)
Visit 12 months vs 6 months 1.10 (0.83 to 1.46)
Predictor Standardized beta-coefficient
(β) (95% CI)
Outcome: presenteeism
Fatigue 3.44 (2.17 to 4.71)
Age (years) 1.44 (0.26 to 2.63)
% impairment while working due to RA 9.36 (7.96 to 10.76)
% impairment at 12 months vs % impairment at 6 months −1.98 (−3.39 to −0.58)
Visit 12 months vs 6 months −1.16 (−2.57 to 0.24)
Outcome: Work productivity loss
Fatigue 4.16 (2.47 to 5.85)
% overall work impairment due to RA 9.43 (7.74 to 11.12)
Visit 12 months vs 6 months −0.60 (−2.64 to 1.44)
Outcome: Activity impairment
Fatigue 1.52 (0.79 to 2.26)
Male vs female −1.83 (−3.33 to −0.33)
Age (years) 3.25 (2.61 to 3.90)
% activity impairment due to RA 9.41 (8.59 to 10.23)
% activity impairment at 12 months vs % activity
impairment at 6 months
−1.92 (−2.67 to −1.18)
Anxiety/depression Some vs none 2.80 (1.40 to 4.20)
Extreme vs none 5.81 (2.82 to 8.79)
Visit 12 months vs 6 months −2.36 (−3.10 to −1.61)
CI, confidence interval; CRP, C-reactive protein; RA, rheumatoid arthritis; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems
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disability have been mostly cross-sectional and have all
reported a significant association between these two fac-
tors [3, 18, 26, 27]. Of the longitudinal assessments,
Zirkzee and colleagues found fatigue to be only weakly
associated (p = .131) with deteriorating work status at
1 year among a small, likely underpowered, sample (n = 69)
of Dutch patients newly diagnosed with inflammatory arth-
ritis [28]. Similarly, fatigue was identified as a significant
univariable, but not multivariable, predictor of receiving a
work disability pension in a Norwegian study (n = 159) that
aimed long-term work disability (the follow-up time point
was 7 years) [29]. However, for patients, the predictors of
shorter-term work disability are likely to be more inform-
ative in the context of preventative intervention develop-
ment. Such future therapies may rescue patients from more
immediate personal financial concerns related to their
employment.
Pre-existing deficiencies in work disability measures
were consistently the strongest predictors of the same
outcome at 1 year. While this is intuitive, more surpris-
ing was the absence of independent associations between
disease activity or pain and work disability.
This observation may reflect the success of biological
therapies in targeting these factors during the follow-up
of these cohorts and subsequently attenuating any asso-
ciation. Although fatigue may also be a mediator of the
relationship between pain or disease activity and work
disability, it is also plausible that no strong relationship
may actually exist between these variables. Certainly, a
previous systematic review only reported inconsistent
evidence for a relationship between these traditional
clinical factors [19].
In keeping with a previous report [30], we have shown
that levels of fatigue and work disability are comparable
between RA and AS working age populations. However,
in this study, fatigue appears to differentially impact the
domains of work impairment in RA and AS. One pos-
sible explanation for this difference may be the (ex-
pected) higher prevalence of males within the AS
cohort. Work disability has previously been found to be
dependent on the work status of the spouse [9], i.e. those
married to a working partner are more likely to reduce/
stop their own work when compromised by disease. In
many cultures, including in Germany, it remains common
for males to adopt the traditional role as the principal eco-
nomic provider for the family unit. Thus, the threshold for
work disability in response to fatigue could be higher as a
result of their greater financial responsibilities. Another
explanation is that the impact of fatigue may be greater
for females compared with males. In rheumatic disease, fa-
tigue is consistently reported to be greater among females
for reasons as yet undetermined [31]. Finally, the nature
of fatigue (and subsequent impact) may be distinct be-
tween AS and RA resulting from separate pathways.
Certainly, in terms of developing preventative inter-
ventions, the differential impact of fatigue as well as the
more prominent association between anxiety/depression
and work disability for AS compared with RA patients
supports the delivery of disease-specific rather than gen-
eric interventions to prevent work disability.
A number of potential limitations should be consid-
ered when interpreting these results. Firstly, participants
were new commencers of biological therapies and so
were not representative of all AS and RA patients. The
majority of RA and AS patients do not receive biological
therapies [32, 33]. Such patients are typically charac-
terised by high levels of disease activity and past disease-
modifying anti-rheumatic drug failure. Data from both
the German and UK biologics registers, which also re-
cruit disease controls, indicate that RA patients not re-
ceiving biologicals are demographically similar, but AS
patients tend to be younger [34–36]. Although it is pos-
sible that these results may not be generalisable, the
population frame (which enables the selection of those
patients with significant work disability despite a trial of
biological therapy) is ideal to help us elucidate those de-
terminants of work disability that are not necessarily
fully related to inflammation (such as fatigue). We also
acknowledge that generalisability of our identified asso-
ciations may be influenced by cultural differences. For
example, attitudes towards work [37], resilience factors
[38], and availability of social security [26] support may
influence the levels of work disability and all may vary
between countries (although this may not necessarily
confound the relationship with fatigue).
Secondly, in the absence of a control group, we cannot
quantify the effect of etanercept on either fatigue or work
productivity. Nevertheless, additional analyses showed
that, among those still taking etanercept at 12 months
(RA n = 1091, AS n = 689), average reductions of 20%
were seen in presenteeism, work productivity loss, and ac-
tivity impairment in both cohorts while absenteeism re-
duced by an average of 8–15% in RA and AS, respectively
(data not shown).
Furthermore, work impairment is likely multifactorial
in origin. While we were able to access data on a num-
ber of factors which are commonly implicated with this
outcome, a number of other potentially interesting vari-
ables, for example sleep disturbance, co-medications,
and disease severity, were not captured by the study
and could not be incorporated into this analysis.
Thirdly, given the observational design of this study,
causality cannot be inferred although it seems quite
possible given what we already know from patient re-
ports. Finally, the psychosocial measures available to us
for this secondary analysis provided only non-specific
global measures of the underlying constructs of
interest. For example, the EQ-5D does not enable the
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relative contributions of anxiety and depression to be
separately determined.
Similarly, we acknowledge that our use of a VAS to
capture fatigue may not have fully captured this com-
plex construct relative to multi-dimensional measures,
such as the Bristol Rheumatoid Arthritis Fatigue Multi-
Dimensional Questionnaire (BRAF MDQ) or Chalder
Fatigue Questionnaire (CFQ) [39]. Fatigue VAS scales
are, however, considered suitable for use for those
seeking to obtain a global measurement of fatigue, and
are sensitive to change and are commonly used, aiding
comparison with other diseases [39].
Future studies should seek to validate these finding
using different fatigue instruments in different sampling
frames. The development of interventions to reduce
work disability among patients with arthritis is a key
priority for patients and researchers alike. The targets
for such interventions are likely to be multiple, but this
study provides evidence that fatigue-specific measures
should be a key component in the development of any
future interventions. Existing evidence supports the ef-
ficacy of non-pharmacological interventions such as ex-
ercise and cognitive behavioural therapies for fatigue in
the context of inflammatory rheumatic diseases [40]. A
better understanding of the biology of fatigue will be
important for the development of alternative therapies
in the future.
Conclusions
This is the largest study to examine the longitudinal as-
sociation between fatigue and work impairment and, by
selecting two cohorts which underwent near-identical
interventions and data collection procedures, the first
to enable the comparison of this relationship between
two different rheumatic diseases. We have demon-
strated that, among patients beginning etanercept ther-
apy, fatigue has a significant effect on the absenteeism,
presenteeism, productivity loss, and activity impairment
of patients with RA, and a significant but dimension-
selective effect on work disability among AS patients.
In addition to pharmacological treatment of inflamma-
tion, fatigue-alleviating interventions such as cognitive
behavioural therapy and exercise should be tested in
both RA and AS patients with a view to modifying the
course of this crucial outcome.
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